Purpose: This study aims to estimate the prevalence and risk factors of diabetic retinopathy (DR) in patients enrolled in a large Danish quality-assuring database for diabetes: the Funen Diabetes Database (FDDB). Methods: All patients with type 1 (T1DM) and type 2 DM (T2DM) diabetes mellitus (DM) were included in a cross-sectional study. The level of DR per patient was determined based on the eye with highest level of DR. All ocular and non-ocular data were extracted at the latest examination that corresponded to the most recent DR-grading data. Results: Data from 17 152 patients were analysed; 83.1% had T2DM. Prevalence of DR was 23.8% (T1DM: 54.3%, T2DM: 21.2%). T1/T2DM patients were statistically significantly different regarding age, duration of diabetes, BMI, systolic blood pressure (BP), cholesterol, LDL cholesterol, HDL cholesterol, triglyceride, s-creatinine and u-albumin (p < 0.001 for all). Increasing level of DR showed statistically significant association with age, duration of diabetes, systolic BP, HbA1c, s-creatinine and u-albumine with increasing level of DR (all are p < 0.001) both T1DM/ T2DM patients. Conclusion: The patients in FDDB had good systemic control with median values of BP, serum lipids, cholesterol and HbA1c all close to or below national guidelines at the time of data extraction, but still a high level of DR was found in this cohort. DR was more common in patients with T1DM than T2DM, but as T2DM patients are more numerous, their level of DR despite acceptable control is still concerning. Most important associated factors for higher levels of DR were age, duration of diabetes, HbA1c, s-creatinine and u-albumine.
Introduction
Worldwide estimates show that people living with DM will increase from 177 million in 2000 to 366 million by 2030 (Wild et al. 2004) . In Denmark, the prevalence of patients with DM has also increased (Carstensen et al. 2008) . Diabetic retinopathy (DR) has a significant impact on individual health, society and healthcare cost (Struijs et al. 2006; Zimmet 2009) . DR is one of the most feared complications of DM, and many patients thrive to reach good control in order not to develop the disease (Murray & Lopez 1997) . Despite tighter regimes to control systemic risk factors, such as DM, BP and cholesterol, DR remains one of the leading causes of visual impairment in industrialized countries. Hence, estimates of prevalence and risk factors for DR are still important (Cheung et al. 2010; Ding & Wong 2012) .
In a population-based cohort of Danish patients with long-term type 1 DM (T1DM), 97% had DR; moreover, during the 25-year follow-up every tenth patient was registered blind (Grauslund et al. 2009a,b) .
Several earlier studies reported the prevalence of DR to be 17.6-33.2% (Yau et al. 2012) . However, many studies are based on earlier finding and limited by smaller sample sizes. Improvements in systemic DM control call for establishing new estimates, which might or might not reproduce the results of older studies. For instance, elevated BP was an important risk factor for DR in the United Kingdom Prospective Diabetes Study (UKPDS; UKPDS 1998), but was not recognized as such in the more recent Action to Control Cardiovascular Risk in Diabetes (ACCORD; Chew et al. 2010) , where overall BP control was much improved.
Introduction of DR Screening in the UK (UK-GOV 2016), together with better control of diabetes and BP, led to DR no longer being the leading cause of blindness in the working age group in the UK, proving that concerted efforts do lead to improvement of such a late outcome (Liew et al. 2014) .
In this study, our aim was to review the prevalence of DR in a large Danish population-based screening setting and to give an updated estimate of risk and correlation factors for DR.
Materials and Methods
The Funen Diabetes database (FDDB) The FDDB was established in 2003 on the island of Funen, Denmark; since then, patients with DM and their healthcare providers have been able to access the latest relevant results including those from general practice (GPs), diabetes consultants and ophthalmologists. All results of body mass index (BMI), BP, blood tests and DR screening have been stored in this single point-of-entry database. All healthcare personal, including GPs, nurses, diabetologists and ophthalmic consultants, have had the opportunity to report their relevant results to the database. A total of approximately 473 000 are living on the island of Funen, Denmark (Danmarks-Statistik 2016) . In 2012, it was estimated that 27 000 were living with DM on the island of Funen equal to approximately 6% of the total population. The FDDB contains data of over 22 000 of such patients with DM, both deceased and current living patients were included (Region-Syddanmark 2016) . Episodes of hypoglycaemia were predominantly self-reported and were only reportable if the patient experienced unconsciousness or needed help from others as a result of hypoglycaemia. Diagnosis of ketoacidosis was reported under the hospitalization section in the majority of the cases or if the following criteria were met, but no hospitalization took place: (1) blood glucose >20 mmol/l; (2) acidosis with either pH <7.3 or plasma bicarbonate or hydrogen carbonate <17 mmol/l; and (3) ketonuria.
Information of other co-morbidity such as ACS and cerebrovascular incidents was obtained from the patient's hospital notes or was self-reported at the time of the patients' next DM clinic appointment, let it be at the hospital or at the GP. Wherever possible, these were verified from clinical entries. Information about angina pectoris and intermittent claudication was based on patients' symptoms and recorded as self-reported complication. Diagnosis of heart failure was entered for patients with New York Heart Association ≥II (NYHA). Information on vascular surgery was obtained from patients' notes or from self-reporting and entered as a operation patients underwent before their eye examination. Kidney failure was deemed present if the patient was either on dialysis or had a kidney transplantation.
Diabetic retinopathy (DR) grading
The ophthalmic images were taken by trained nurses, optometrists and ophthalmologist at OUH and also by any of the 14 trained and accredited private ophthalmologists, all of whom had been granted access to FDDB once they were competent in completing the necessary fields and were able to take good-quality images through dilated pupils. At OUH, 6-field fundus images of 45 degrees in each eye were taken (Topcon TRC-NW8; Topcon, Tokyo, Japan), where one image were centred at the disc, one at the fovea, one superior and inferior temporal to the fovea and one superior and interior nasal to the optic disc. Most practising private ophthalmologist took the standard 2-field fundus images of 45 degrees with one centred at the macula and one centred at the optic disc (Aldington et al. 1995) . Once the images were captured, authorized personnel graded the images according to the International Clinical Diabetic Retinopathy (ICDR) and Diabetic Macular Edema Disease Severity Scale (Wilkinson et al. 2003) . Each eye was categorized into no apparent DR (DR = 0), mild non-proliferative DR (NPDR; DR = 1) with microaneurysm (s) only and moderate NPDR (DR = 2) with more changes than mild NPDR but less than severe NPDR (DR = 3). Severe NPDR was defined according to the Early Treatment Diabetic Retinopathy Study (ETDRS; ETDRS 1991) 4:2:1 rule: >20 intraretinal haemorrhages in all four retinal quadrants or definite venous beading in ≥2 quadrants or prominent intraretinal microvascular abnormalities (IRMA) ≥1 quadrant. Proliferative diabetic retinopathy (PDR; DR = 4) was defined as neovascularization(s) either on the disc and/or elsewhere and/or vitreous or preretinal haemorrhages.
Ethical approval
This study followed the Helsinki declaration. Approval of data extraction was applied for and approved by FDDB administration at OUH. The Danish Data Protection Agency and The National Committee on Health Research approved analysis of data.
Data extraction
At the point of data extraction on 28 November 2014, the FDDB contained 22 098 patients with DM from the Danish island of Funen with available ophthalmic data so all anonymized results for every one of these patients were extracted from FDDB. As all data were anonymized at extraction, no additional written consent was needed from the participants according to ethical approval. No exclusion was made at extraction time, and every patient with ophthalmic data in the FDDB was included in this study. If the patient was deceased (3501 patients) prior to extraction date, their last available data were used.
Data clarification and cleaning
As a first step, all data underwent analysis for outliers and impossible values, which were then verified from other hospital or GP notes, or from laboratory records to be within valid values for every category. Only true and verifiable outliers were removed. Extreme, but valid measures were kept. Nine patients were excluded due to a negative duration of diabetes as dates of diagnoses of DM were recorded after latest DR screening and the actual date of diagnosis could not be verified.
Results for height and weight were analysed along with BMI results, and where impossible values were found, the FDDB team clarified the result. BP values were all found to be within biologically valid, measurable levels with standard BP kits.
If a typing error was confirmed, and a correct value was available, this was substituted in the database and used for analysis. Biologically impossible values where clarification was not possible were set as missing.
Episodes of co-morbidity such as hypo-and hyperglycaemia, ketoacidosis, kidney and heart failure, ACS and cerebrovascular disease were not corrected as they were biologically valid values and were originally obtained from patient's hospital notes and hospitalization and by self-reporting.
All biochemical results and their normal/possible measurable range were confirmed by the department of Clinical Biochemistry and Pharmacology, OUH, and so only data within the valid and reliable range from OUH were included for analysing.
Statistical analysis
Data were first analysed for all patients and all data. Subsequently, the cohort was divided into two groups (T1DM and T2DM) and analysed accordingly.
All continuous data went through a Shapiro-Wilk test of normality to test for normal distribution. A histogram view was used to determine whether the data contained outliers or impossible values.
For variables that failed the test for normal distribution, nonparametric tests were used. A Mann-Whitney Utest was used to test for differences between two groups with continuous data and chi-square was used to test for differences and trend for categorical data. For continuous data, KruskalWallis test was used to test for differences and Jonckheere Terpstra Trend test was used to test for trend (Bewick et al. 2004 ). Kendall's tau b test was used to determine the correlation and effect size across DR levels.
A multivariate analysis for odds ratio of DR versus no-DR was made. For this analysis, urine albumin and creatinine clearance were excluded due to the magnitude of missing data. Results of co-morbidities were also left out of the multivariate analysis due to inability to verify if no entry meant 'no disease' or 'not entered'. The continuous risk factor results were transformed into interval groups for better performance of the analysis. These intervals are added to the result table. Significance level was set to 0.05 for all analyses.
Statistical analysis was performed using SPSS, version 22.0.0.0 (IBM Corporation, worldwide, New York, NY, USA).
Results

Univariate results for general population and DM types
Overall patient characteristics of the FDDB cohort
Of the 22 098 patients in the database, 17 152 had a known DM type (77.6%), of which 2901 had T1DM (16.9%) and 14 251 had T2DM (83.1%; Table 1 ). There was 22.4% of the whole database with undetermined type of DM. Of patients with known DM type, 9767 patients (56.9%) were men.
As presented in Table 1 , 12 factors differed between patients with T1DM and T2DM; most importantly, patients with T2DM patients were older and had shorter duration of DM, higher 
BMI and lower HbA1c than patients with T1D. A comparison between men and women did not show a tendency or differences in tested parameters (data not shown).
Age distribution Figure 1 shows the age distribution of the cohort divided into <18 years of age, 18-40 years and then 10-year intervals thereafter. T1DM patients tended to be younger in age with most patients in the under 40 age group. T2DM patients tended to be older, and the groups above 60 years of age accounted for 76.6%.
Diabetic retinopathy (DR)
Prevalence of any DR was 23.8% for all patients with known DM types, however differed between the two types, in the T1DM group was 54.3% and in T2DM was 21.2%. The distribution of the different severity of DR within each diabetes type is shown in Fig. 2 . In summary, a higher percentage of T1DM patients had higher levels of DR as compared to patients with T2DM (p < 0.001, chisquared test).
Associations between type of DM, DR and other values
T1DM
The highest correlation is for levels of DR and duration of diabetes (0.430) as shown in Table 2 . None of the other factors showed the same magnitude of association, but there were several with clinical significance, such as u-albumin (0.194), s-creatinine (0.161), age (0.140), systolic BP (0.120) and HbA1c (0.112) while increasing DR level showed a negative trend for creatinine clearance as expected (À0.116). Data are shown in Table 2 .
T2DM
Data for T2DM are shown in Table 3 . Duration of DM showed the highest correlation (0.306) with the level of DR. High associations with DR were also found for HbA1c (0.162), ualbumin (0.122) and s-creatinine (0.114), while creatinine clearance showed a negative trend (À0.117). No trend was seen for BMI (p-value 0.175, Jonckheere Terpstra Trend test) and triglyceride (p-value 0.196).
Co-morbidity
Results for co-morbidity are shown in Table 4 . More than half of the patients with PDR in T1DM had experienced at least one episode of hypoglycaemia, and this group also had more patients with more than five episodes as compared to lower levels of DR. There was an increasing trend of episodes of hypoglycaemia, ACS, cerebrovascular incidents and kidney failures for both DM types with increasing levels of DR (p < 0.0001 for both).
Multivariate analysis of risk factors for DR
Multivariable odds ratio (OR) analysis was performed for the risk factors presented in Tables 2 and 3 . Shown in Table 5 are the results for both T1DM and T2DM for this analysis. The risk factors are shown with their new interval for better analysis.
The results showed significant results of duration of DM, BMI, HbA1c and s-creatinine all affecting progression of DR in both T1DM and T2DM. Duration of DM showed to be the most dominant with OR of 1.39 (95% CI 1.33-1.45) for T1DM and 1.75 (95% CI 1.69-1.81) for T2DM. Systolic BP and HDL showed significant OR of 1.16 (95% CI 1.03-1.31) and 1.15 (95% CI 1.01-1.30), respectively, in T1DM patients.
Discussion
We examined epidemiological, hospital, laboratory and DR severity data from patients from a large populationbased DR screening database to estimate the prevalence and risk profile for DR in the Danish population of Funen. We showed a significant difference in prevalence of any DR between T1DM (54.3%) and T2DM (21.2%), which was comparable to a recent study from Wales (Thomas et al. 2015) . Our results are also not vastly dissimilar to a Swedish populationbased study where prevalence of 41.8% for any DR in T1DM and of 27.9% in T2DM were found (Heintz et al. 2010), but they show lower prevalence of DR in T1DM but higher in T2DM compared to our study. Data from the Saudi National Diabetes Registry of 50 464 patients showed a prevalence of DR in T2DM patients of 19.7% (Al-Rubeaan et al. 2015) , which is close to our 21.2% prevalence, but their PDR was about four times higher than ours (10.6% in Saudi versus 2.7% in Funen). The Wisconsin Epidemiological Study of Diabetic Retinopathy (WESDR) 30 years ago found that the DR prevalence in T1DM varied from 17% to 96.5% between those with <5 years of duration and those with longer than 15-year duration, respectively. Corresponding numbers for patients with T2DM were 28.8-77.8% (Klein et al. 1984a,b) . The FDDB cohort showed a decrease in prevalence of DR in T2DM as compared to the WESDR (Klein et al. 1984b ). This might suggest that newer and more intensive treatment regimens might have led to a decreasing prevalence of DR, at least in our cohort, or might be related to the intensive DM screening leading to early diagnosis of the disease and less patients developing DR 5 and 15 years of duration. Even though patients in the FDDB in general were well controlled at the time of data extraction, many still developed DR, suggesting that despite advances in diagnosis and treatment of DM there is still need for improvement in systemic control to prevent or at least delay development of DR. Our current data set only contains patients' latest results at the time of data extraction, and therefore, it does not allow for analysis of historical results on how good patients were controlled throughout the years. This requires further investigation in the database to fully understand each patient's progression of DR compared to their diabetes control prior to our analysis.
Comparing results for T1DM and T2DM showed statistical significant different distributions in age, duration of DM, best-corrected visual acuity (BCVA), BMI, systolic BP, HbA1c, cholesterol, LDL, HDL, triglyceride, creatinine and albumin but not in diastolic BP and creatinine clearance. T2DM patients were older and had shorter DM duration and lower HbA1c as the most dominant differences. These were in keeping with known data from previous studies. Overall patients had good HbA1c levels in accordance with the Danish national guidelines (from Danish Endocrine Society (DES); DES 2016a, b). However, even within this wellcontrolled cohort, results still showed that increasing HbA1c was associated with increasing DR level in both T1DM and T2DM groups and therefore supports the notion of striving for the achievement of the best available control.
United Kingdom Prospective Diabetes Study (Kohner et al. 1998 ; UKPDS 1998) demonstrated that elevated BP was a risk factor for DR, and in keeping with this, we found a slight trend of higher systolic BP in patients with higher levels of DR level for both types of diabetes, but median levels were still below national recommendations (Bang et al. 2009; Bech et al. 2015) . Our results showed that even with median systolic BP below guidelines, it still plays a small role as an associated factor for DR. Therefore, our results do not confirm the results from the ACCORD study (Chew et al. 2010) .
No clear trends were seen for triglyceride, HDL, LDL and cholesterol in either of DM types. Those parameters that showed a significant trend (triglyceride in T1DM and LDL, HDL and cholesterol in T2DM) were all very small. None of the lipid median values were outside recommended Danish guidelines. The same were seen in the multivariate analysis where only HDL in T1DM showed significant to progression to retinopathy.
As the vast majority of the patients were overweight in T2DM, it might explain why BMI did not contribute significantly to DR severity. In T1DM, BMI showed an increasing trend across DR level. Also, in the multivariate analysis BMI showed more significant in T1DM with OR of 1.17 compared to T2DM with OR of 1.05.
Diabetes mellitus patients are known to have a higher risk to develop microvascular complications, including diabetic kidney disease (Struijs et al. 2006; Zimmet 2009 ). This was clearly demonstrated in this study as we noted increasing s-creatinine levels with increasing levels of DR. In T1DM, for patients with PDR, median values of renal markers were above international guidelines (American Diabetes Association 2013). In T2DM, this was 
Age ( the case with patients from moderate NPDR to PDR. PDR patients in T1DM and severe NPDR and PDR patients in T2DM showed median values equal to diagnosis of microalbuminuria. Rates of kidney failure also increased with increased DR levels.
As in other cohorts, T1DM patients presented with more episodes of hypoglycaemia (about 13% of T1DM patients and only two % of patients with T2DM). Episodes of hypoglycaemia might not directly affect progression of DR. However, too many episodes of hypoglycaemia lead to an increase in recommended level of HbA1c, and thereby, indirectly it might affect DR progression (DES 2016b). As expected, T1DM had more episodes of ketoacidosis than T2DM. There was no correlation between episodes of ketoacidosis and level of DR in the T1DM population.
Acute coronary syndrome (ACS) and cerebrovascular incidents showed a tendency for both T1DM and T2DM patients to have increased episodes with increased DR level. Patients with T2DM more often had these co-morbidities than T1DM. This was expected, as T2DM patients generally were older than T1DM patients and therefore had a higher risk of developing macrovascular complications as well.
Although co-morbidities show some correlations between DR grade, they have to be considered as less substantial as the measured values such as blood sample values and BP. This is due to multiple departments being involved in treating patients, and therefore, some data are not entered into the database, and some data are obtained through self-reporting.
The multivariate analysis showed some additional information of risk factors for progression from no-DR to DR. Duration of DM showed the highest OR of the significant results for both DM types (1.39 for T1DM and 1.75 for T2DM). In T1DM, screatinine showed second highest with OR of 1.26 with an increase of 25 lmol/l, and this shows us as known a close relation to DM severity and nephropathy. HbA1c and BMI showed OR of 1.15 and 1.17, respectively, and were main contributors to retinopathy progression in T1DM, and both risk factors are well known to contribute to DR progression (Klein et al. 1997; Mohamed et al. 2007; Ting et al. 2016) . In T2DM, HbA1c showed second highest OR of 1.26 for every increase of 10 mmol/mol, and again s-creatinine showed a significant OR of 1.10 but not as dominant as in T1DM.
Compared to the results of correlations and trends in Tables 2 and 3 , the main difference to the multivariate analysis is the missing effect of age, in particular for T1DM where the correlation was higher than T2DM with increasing DR severity. In our results, age do not show as a dominant risk factor. To sum up the results from multivariate analysis in Table 5 , the main risk factor for both DM types was duration of DM and HbA1c level as shown in other studies (DCCT 1993; Stratton et al. 2001; Yau et al. 2012; Ting et al. 2016) .
The biggest strengths of this study are the cohort size with over 17 000 patients and the number of parameters collected systematically since 2003 in the FDDB database. We hereby show the FDDB database's ability to be used for ophthalmic health research in relation to DR and, in general, aspects of diabetes care. Therefore, based on this study, it is feasible to further analyse the data from the FDDB and it is likely to provide further insight into patients' health and well-being in Funen.
A weakness within the FDDB was the multiple grading sites and thereby multiple graders, along with the difference in the protocol for retinal field images (between two and six retinal fields). In addition, certain variables have substantial amount of missing data especially for co-morbidities where data source can either be selfreported or from patients' clinical notes, and it is a possibility that some events were not entered. This gives a skewed distribution in the amount of data available for each parameter tested, meaning blood results, BP and BMI being more reliable than selfreported co-morbidities.
Generally, the Danish population of patients with DM is well controlled with acceptable levels of HbA1c and lipids and BP values according to guidelines (American Diabetes Association 2013; DES 2016a,b) . Even though most patients in the FDDB were well controlled at the time of sampling, with the main risk factors being increasing age, duration of DM, HbA1c level and BMI, some still developed PDR at a similar extent as in other studies. This requires further investigation and could be future ophthalmic perspective on the data from the FDDB, by extracting data from years back to follow patients' progression of DR. Age = Age at last ophthalmic examination, BMI = body mass index, BP = blood pressure, s = serum.
